Tissue TransplantationComplicityFetal Tissue TransplantationPersonhoodDirected Tissue DonationLifeBeginning of Human LifeBrain Tissue TransplantationAborted FetusTissue and Organ ProcurementHospitals, StateOrgan TransplantationLiver TransplantationHand TransplantationTransplantation, HeterotopicTransplantation, HomologousTransplantationTissue DonorsTransplantation ImmunologyKidney TransplantationGraft SurvivalPregnant WomenBone Marrow TransplantationPrimary Ovarian InsufficiencyEthics, MedicalSkin TransplantationHematopoietic Stem Cell TransplantationCryopreservationHeart TransplantationTransplantation, AutologousLung TransplantationStem Cell TransplantationTransplantation ConditioningOvaryGraft RejectionPancreas TransplantationIslets of Langerhans TransplantationCell TransplantationTransplantation ChimeraImmunosuppressive AgentsGraft vs Host DiseaseTransplantation, IsogeneicLiving DonorsTreatment OutcomeCord Blood Stem Cell TransplantationHeart-Lung TransplantationTransplantation TolerancePeripheral Blood Stem Cell TransplantationLiver FailureRetrospective StudiesImmunosuppressionHistocompatibility TestingTime FactorsPostoperative ComplicationsWaiting ListsTransplantation, HeterologousRecurrenceMesenchymal Stem Cell TransplantationCorneal TransplantationHistocompatibilityHematologic NeoplasmsTacrolimusWhole-Body IrradiationCyclosporineFollow-Up StudiesCadaverSurvival AnalysisSurvival RateFacial TransplantationDonor SelectionLiver DiseasesOrgan PreservationBusulfanTransplantsHLA AntigensKidney Failure, ChronicLeukemiaBronchiolitis ObliteransCombined Modality TherapyRisk FactorsAntilymphocyte SerumRemission InductionAnemia, AplasticBlood Group IncompatibilityCytomegalovirus InfectionsMycophenolic AcidPostoperative PeriodMyeloablative AgonistsAcute DiseaseHematopoietic Stem CellsTissue and Organ HarvestingRats, Inbred LewMice, Inbred C57BLCyclophosphamidePrognosisEnd Stage Liver DiseaseLiverNeoplasm TransplantationPatient SelectionDisease-Free Survival